Ultragenyx stock crashed Thursday, losing almost half its value, after its experimental Angelman treatment failed in final-phase testing.
Yahoo
Skip to navigation
Skip to main content
Skip to right column
Ultragenyx's 'Fall From Grace' — Shares Crash 44%, Hitting A Record Low ·
Investor's Business Daily
